Search results for Tocilizumab ELISA Kit
Tocilizumab ELISA Kit, ProteoGenix, KPTX164
Description of Tocilizumab ELISA Kit Tocilizumab ELISA Kit: A Comprehensive Guide Introduction Tocilizumab is a humanized monoclonal antibody that specifically targets the interleukin-6 (IL-6) receptor. It is used as a therapeutic agent for the treatment of various inflammatory diseases, including rheumatoid arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome. The Tocilizumab ELISA Kit is a highly sensitive and reliable tool for the detection and quantification of Tocilizumab in biological samples. In this article, we will provide a detailed description of the structure, activity, and application of this ELISA Kit. Structure of Tocilizumab Tocilizumab is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 148 kDa. The antibody is produced by recombinant DNA technology using Chinese hamster ovary (CHO) cells. It binds to the IL-6 receptor with high affinity, preventing IL-6 from binding to its receptor and inhibiting downstream signaling pathways. Activity of Tocilizumab Tocilizumab exerts its therapeutic effects by blocking the activity of IL-6, a pro-inflammatory cytokine that plays a key role in the pathogenesis of various inflammatory diseases. IL-6 is produced by a variety of cells, including immune cells, and is involved in the regulation of immune responses, hematopoiesis, and acute-phase reactions. Overproduction of IL-6 has been linked to the development of autoimmune disorders and chronic inflammatory conditions. By blocking the IL-6 receptor, Tocilizumab inhibits the downstream signaling pathways, leading to reduced inflammation and improved clinical outcomes. Application of Tocilizumab ELISA Kit The Tocilizumab ELISA Kit is a valuable tool for the detection and quantification of Tocilizumab in various biological samples, including serum, plasma, and cell culture supernatants. It is a highly sensitive and specific assay that utilizes the sandwich ELISA principle, where Tocilizumab is captured by a specific anti-Tocilizumab antibody coated on the microplate wells, and then detected by a second biotinylated anti-Tocilizumab antibody and streptavidin-HRP conjugate. The colorimetric signal is then measured and quantified using a microplate reader, with the intensity of the signal directly proportional to the amount of Tocilizumab present in the sample. The Tocilizumab ELISA Kit is widely used in clinical and research settings for the measurement of Tocilizumab levels in patient samples. It is an essential tool for monitoring Tocilizumab therapy and assessing treatment response in patients with inflammatory diseases. In addition, the kit can also be used for pharmacokinetic studies to determine the pharmacokinetic parameters of Tocilizumab, such as peak serum concentration and elimination half-life. Conclusion The Tocilizumab ELISA Kit is a valuable tool for the detection and quantification of Tocilizumab, a humanized monoclonal antibody used as a therapeutic agent for the treatment of inflammatory diseases. The kit provides a reliable and sensitive method for monitoring Tocilizumab therapy and assessing treatment response in patients. Its wide range of applications makes it an essential tool for both clinical and research settings. With its high specificity and sensitivity, the Tocilizumab ELISA Kit is a crucial asset in the field of immunology and drug development. Keywords: Tocilizumab, ELISA Kit, antibody, therapeutic target, IL-6 receptor, inflammatory diseases
Host
Reactivity
Applications
Conjugation
Tocilizumab ELISA Kit, Abbexa, abx395053
Tocilizumab ELISA Kit is a quantitative ELISA kit for detection of Tocilizumab.Tocilizumab is a humanized IgG1 monoclonal antibody to the IL-6 receptor that is used largely as therapy of refractory rheumatoid arthritis and other inflammatory arthritides. Tocilizumab blocks the action of IL-6, which is a key proinflammatory cytokine that mediates a wide spectrum of biologic activities including activation of T cells, differentiation of B cells, induction of acute phase reactants, proliferation of fibroblasts, and damage to cartilage and joints. IL-6 levels are elevated in patients with active rheumatoid arthritis. In controlled trials and open label studies, tocilizumab therapy led to improvements in symptoms and laboratory abnormalities associated with several forms of inflammatory arthritis. Tocilizumab was approved for use in the United States in 2010 and current indications include rheumatoid arthritis, giant cell arteritis and both the polyarticular and systemic forms of juvenile idiopathic arthritis (formerly juvenile rheumatoid arthritis). Tocilizumab is considered a disease modifying antirheumatic drug (DMARD) and improves signs and symptoms of disease and decreases cartilage and tissue destruction.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.